
Maars Formulations Private Limited
About Maars Formulations Private Limited
Data last updated:
Maars Formulations Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 07 May 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24304DL2019PTC349664. Its GSTIN is 09AAMCM6520E1ZF (Uttar Pradesh).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Pankaj Rani Mayur and Naveen Kaushik.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at H.No. 367 Block G Pocket 6 Section 16 Rohini, New Delhi, Delhi, India – 110085.
As per the financials filed for FY 2025, the company reported a revenue of ₹36.53 Lakh, a growth of 15% compared to the previous year. For the same year it recorded a net profit of ₹51,055 (net margin 1.4%) and EBITDA of ₹56,170 (EBITDA margin 1.5%). Revenue has grown at a compounded annual rate (CAGR) of 1% over three years and 30% over five years.
Company details
Contact details
Maars Formulations Private Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressH.No. 367 Block G Pocket 6 Section 16 Rohini, New Delhi, Delhi, India – 110085
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Maars Formulations Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Maars Formulations is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Maars Formulations Private Limited, buy the company report.
Financials of Maars Formulations Private Limited
FY 2025 filings availableMaars Formulations Private Limited reported revenue of ₹36.53 Lakh (up 15% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 30% over five years, including 15% growth in the latest year. EBITDA rose 163% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹56,170 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹51,055 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 1.5% | ||||
| Net Profit Margin | 1.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Maars Formulations Private Limited, buy the company report.
Board of directors of Maars Formulations Private Limited
Maars Formulations has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pankaj Rani Mayur | Director | 02 Jul 2021 | 5 Years 4 Months | Current |
| Naveen Kaushik | Director | 07 May 2019 | 7 Years 6 Months | Current |
Peer comparison
Maars Formulations Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Formulations, Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Lumos Drugs & Surgical Private Limited | ₹36.56 Lakh (FY 2025) | 137.0% | Guwahati, Assam, India | |||
| Maars Formulations Private Limitedthis company | ₹36.53 Lakh (FY 2025) | ₹51,055 | 1.4% | 15.0% | New Delhi, Delhi, India | |
| Zdravi Duvera India Limited | ₹36.53 Lakh (FY 2018) | -42.0% | Navi Mumbai, Maharashtra, India | |||
| Rmanirex Pharma Private Limited | ₹36.41 Lakh (FY 2025) | -18.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Maars Formulations Private Limited, buy the company report.
Auditor
Maars Formulations Private Limited is audited by A K S G & ASSOCIATES for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| A K S G & ASSOCIATES | FY 2022 | 018932C |
Shareholding
The shareholding of Maars Formulations Private Limited is on record for 2 financial years, the latest being FY 2021, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2021 | FY 2020 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Maars Formulations Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Maars Formulations Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Maars Formulations Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Maars Formulations has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAMCM6520E1ZF | Uttar Pradesh | Active | 16 May 2019 |
To see the full GST registrations and return filing status of Maars Formulations Private Limited, buy the company report.
Recent activity
Maars Formulations Private Limited has 4 board changes on record since 2019: 2 appointments and 2 cessations. The latest: Vishesh Sharma ceased to be Director on 12 Jan 2023.
Frequently asked questions
Maars Formulations is an active private limited company based in New Delhi, Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 07 May 2019 (7+ years old) and is registered under CIN U24304DL2019PTC349664.
Maars Formulations has 2 current directors:
- Pankaj Rani Mayur - Director
- Naveen Kaushik - Director
The latest financial statements of Maars Formulations on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Maars Formulations is 09AAMCM6520E1ZF, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Maars Formulations is U24304DL2019PTC349664. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Maars Formulations was incorporated on 07 May 2019, making it 7+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Maars Formulations by revenue are Lumos Drugs & Surgical Private Limited, Zdravi Duvera India Limited, Rmanirex Pharma Private Limited, all in the Pharma industry (Formulations, Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Vishesh Sharma ceased to be Director on 12 Jan 2023. Gufran . ceased to be Director on 16 Feb 2022. Pankaj Rani Mayur was appointed as Director on 02 Jul 2021. Maars Formulations has 4 board changes on record in total.
The registered office of Maars Formulations is at H.No. 367 Block G Pocket 6 Section 16 Rohini, New Delhi, Delhi, India – 110085.
Maars Formulations operates in the pharma industry, in the pharmaceutical retailers and distributors segment.
Maars Formulations can be reached at its registered office: H.No. 367 Block G Pocket 6 Section 16 Rohini, New Delhi, Delhi, India – 110085.

